Holen Sie sich die Stockscreener-App
24.73
3.87%
-1.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$25.81
Offen:
$28.48
24-Stunden-Volumen:
1.76M
Relative Volume:
0.83
Marktkapitalisierung:
$2.44B
Einnahmen:
$669.43M
Nettoeinkommen (Verlust:
$-609.36M
KGV:
-4.05
EPS:
-6.1061
Netto-Cashflow:
$-507.20M
1W Leistung:
-0.76%
1M Leistung:
-25.87%
6M Leistung:
+4.29%
1J Leistung:
-14.21%
1-Tages-Spanne:
$24.73
$28.48
1-Wochen-Bereich:
$24.01
$28.48
52-Wochen-Spanne:
$18.29
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
24.74 | 2.65B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
484.80 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
763.74 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.49 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
327.82 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Danaher (DHR) - The Globe and Mail
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline - Yahoo Finance UK
RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease - STAT
Ultragenyx Pharmaceutical, Inc. Revenue Breakdown – BIVA:RARE - TradingView
Ultragenyx Pharmaceutical Inc (RARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RARE|Ultragenyx Pharmaceutical Inc|Price:26.900|Chg%:-0.120 - TradingKey
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Ultragenyx Pharmaceutical Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh - TradingView
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Ultragenyx
Ultragenyx New Hires Get Stock Awards, 25% Vests Yearly - Stock Titan
Ultragenyx Pharmaceutical Inc (RARE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Ultragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spree - Trefis
Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss - Trefis
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring an 84% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RARE stock reflects Ultragenyx cash position and recent clinical progress - AD HOC NEWS
Ultragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focus - Sahm
Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024 -- Data Talk - Moomoo
RARE stock rises after Ultragenyx reports strong Crysvita revenue growth and narrows quarterly loss - Ad-hoc-news.de
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Law firm probes Ultragenyx officers for alleged false statements on drug trial results - Pluang
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $48 - Moomoo
Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo
Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm
Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa
Ultragenyx releases 2025 impact report on rare disease work - Investing.com
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times
Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative
Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire
Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $72 - Moomoo
Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa
Form 4 Ultragenyx For: 6 July By Investing.com - Investing.com South Africa
Ultragenyx CFO Howard Horn sells $155,644 in company shares - Investing.com
Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit - 富途牛牛
RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ultragenyx Pharmaceutical Inc-Aktie (RARE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Horn Howard | Chief Financial Officer |
Jul 01 '26 |
Sale |
33.13 |
4,698 |
155,645 |
100,991 |
0.28%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):